Multiple sclerosis, osteoporosis, and vitamin D

Stuart SchlossmanAging & MS, Wellness for MS

 Chrissa Sioka 1Athanassios P KyritsisAndreas Fotopoulos

Affiliations 

Abstract

Multiple sclerosis (MS) is associated with reduced bone mass and higher frequency of osteoporosis. Although high-dose short-term intravenous glucocorticoid regimens cause a decrease in bone formation, this effect is usually reversible and osteoporosis in MS patients may be independent of the short-term corticosteroid treatment. Clinical evidence suggests an important role of vitamin D as a modifiable risk factor in MS. Low circulating levels of vitamin D have been found in MS patients, especially during relapses, suggesting that vitamin D could be involved in the regulation of the clinical disease activity. Vitamin D mediates its function through a single vitamin D receptor (VDR). Polymorphisms of the VDR have major effects on vitamin D function and metabolism, and some VDR genotypes have been linked to osteoporosis and MS. Because the safety of high doses of vitamin D has not been established yet, vitamin D hasn’t been used in enough doses to increase the serum level to a desired therapeutic target. Future clinical trials should determine the upper limit of vitamin D intake in order to achieve therapeutic benefit in MS patients. 

Similar articles  click here to continue reading

Stay informed with MS information, news and resources. Sign-up Here: https://bit.ly/3NkMIeR 

Visit the MS Views and News articles and videos archives: https://wwwmsviewsandrelatednews.blog

Visit us on Facebook:  www.facebook.com/msviewsandnews 

Visit us on Twitter (X): www.twitter.com/MSViewsandNews 

Visit us on Instagram: www.instagram.com/msviewsandnews 

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews